* Tonix Pharmaceuticals Holding Corp reported a quarterly adjusted loss of 23 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-58.56. The mean expectation of three analysts for the quarter was for a loss of $2.93 per share. Wall Street expected results to range from $-7.36 to -40 cents per share.
* Revenue fell 29.3% to $2.82 million from a year ago; analysts expected $3.08 million.
* Tonix Pharmaceuticals Holding Corp's reported EPS for the quarter was a loss of 23 cents.
* The company reported a quarterly loss of $14.21 million.
* Tonix Pharmaceuticals Holding Corp shares had fallen by 5.5% this quarter and lost 98.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 5.7% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is 11.00 This summary was machine generated from LSEG data November 12 at 03:27 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -2.93 -0.23 Beat
Jun. 30 2024 -3.27 -19.28 Missed
Mar. 31 2024 -12.48 -5.76 Beat
Dec. 31 2023 -52.59 -27.52 Beat
